From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Indian pharmaceutical companies head into 2026 with a clearer tilt towards specialty medicines as sustained pricing pressure continues to weigh on returns from traditional generics. With export ...

Bhartha Mahasayulaku Wignyapthi’s team did well to prepare viewers for what they could expect from the Sankranti release. Despite its done-to-death premise of a cheating husband sandwiched between two ...

The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Ozempic, pictured in ...

Danish drug maker Novo Nordisk is preparing to introduce a new version of its blockbuster drug Ozempic to compete with cheaper generics that became legal on Monday, but which are not expected to hit ...

Drug companies in Canada are allowed to make lower priced generic versions of the blockbuster drug Ozempic as of next week, but experts say patients shouldn’t expect it to be available for at least a ...

Canadian employers and their employees can expect to see drug plan savings as generic versions of diabetes and obesity medications are introduced, cutting insurance costs. Ozempic and Wegovy – two ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...